AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

Claim 1 (currently amended): ~~Use of~~ A method for lowering sex hormone levels in an individual, comprising administering to an individual appropriate doses of an LHRH-antagonist, peptidic or non-peptidic, ~~that will lower~~ wherein sex hormone levels in said individual are lowered to a certain extent but not below the castration level of said individual.

Claim 2 (currently amended): ~~Use of~~ A method for lowering sex hormone levels in an individual, comprising administering appropriate doses of an LHRH-antagonist ~~to lower~~ to an individual wherein the lowered sex hormone levels ~~resulting~~ in said individual result in modification of the T-cell population in said individual.

Claim 3 (currently amended): ~~Use of~~ A method for lowering sex hormone levels in an individual, comprising administering appropriate doses of an LHRH-antagonist ~~to lower~~ to an individual wherein the lowered sex hormone levels ~~resulting~~ in said individual result in a modification of the T-cell population in ~~an~~ said individual suffering from a disease that will respond favourably to such a modification.

Claim 4 (currently amended): ~~Use of~~ A method for lowering sex hormone levels in an individual, comprising administering appropriate doses of an LHRH-antagonist ~~to lower~~ to an individual wherein the lowered sex hormone levels ~~resulting~~ in said individual result in a modification of the T-cell population in an individual suffering from a HIV infection, cancer, an auto-immune disease, benign prostatic hyperplasia, endometriosis, asthma, arthritis, dermatitis, multiple sclerosis, Jacob Creuzfeldt-disease, or Alzheimer's disease ~~an for anti-aging treatment~~.

Claim 5 (currently amended): ~~Use of~~ A method for lowering sex hormone levels in an individual, comprising administering appropriate doses of an LHRH-antagonist ~~to lower~~ to an individual wherein the lowered sex hormone levels ~~resulting~~ in said individual result in a modification of the T-cell population resulting in an enhanced immune response to an antigen.

Claim 6 (currently amended): ~~Use of~~ A method for lowering sex hormone levels in an individual, comprising administering appropriate doses of an LHRH-antagonist ~~to lower~~ to an individual wherein the lowered sex hormone levels ~~resulting~~ in said individual result in a modification of the T-cell population resulting in a decrease of host versus graft reaction.

Claim 7 (withdrawn): Examples for substances that can be used as LHRH-antagonists according to claims 1-6 are cetrorelix, teverelix, antide, or abarelix.

Claim 8 (withdrawn): Use of a LHRH-antagonist for producing a medicament for the treatment of diseases according to claims 1 to 7.

Claim 9 (withdrawn): Use according to claim 8, characterized in that the LHRH-antagonist is administered in the following total dose from 5 mg to 120 mg divided in a period of 1 to 8 weeks and according to needs with repeat of the therapy every 3 to 4 months.

Claim 10 (withdrawn): Use according to claims 8 and 9, characterized in that cetrorelix pamoate is administered in the following total dose from 30 mg to 120 mg divided in a period of 1 to 4 weeks and according to needs with repeat of the therapy every 3 to 4 months.

Claim 11 (withdrawn): Use according to claims 8 and 9, characterized in that cetrorelix acetate is administered in teh following total dose from 5 mg to 80 mg divided in a period of 1 to 8 weeks and according to needs with repeat of the therapy every 3 to 4 months.

Claim 12 (new): The method according to any one of claims 1-6, wherein the LHRH-antagonist is chosen from cetrorelix, teverelix, antide, or abarelix.

Claim 13 (new): The method according to any one of claims 1-6, wherein the LHRH-antagonists is cetrorelix or a pharmaceutically acceptable salt form thereof.

Claim 14 (new): The method according to any one of claims 1-6, wherein the appropriate doses of an LHRH-antagonist are determined from a total dosage range of 5 mg to 120 mg divided in a period of 1 to 8 weeks according to needs of the individual with repeat of the therapy every 3 to 4 months.

Claim 15 (new): The method according to any one of claims 1-6, wherein the LHRH-antagonist cetrorelix pamoate is administered in a dosage amount determined from a total dosage range of 30 mg to 120 mg divided in a period of 1 to 4 weeks according to needs, with repeat of the therapy method every 3 to 4 months as needed.

Claim 16 (new): The method according to any one of claims 1-6, wherein the LHRH-antagonist cetrorelix acetate is administered in a dosage amount determined from a total dosage range of 5 mg to 80 mg divided in a period of 1 to 8 weeks according to needs, with repeat of the therapy method every 3 to 4 months as needed.